S&P 500   4,584.47 (+0.77%)
DOW   36,092.99 (+0.11%)
QQQ   390.26 (+1.35%)
AAPL   194.74 (+1.26%)
MSFT   370.38 (+0.43%)
META   327.52 (+3.17%)
GOOGL   138.24 (+6.32%)
AMZN   147.00 (+1.72%)
TSLA   241.87 (+1.04%)
NVDA   462.66 (+1.68%)
NIO   7.45 (-3.87%)
BABA   72.19 (+0.98%)
AMD   125.26 (+7.22%)
T   17.08 (+0.83%)
F   10.80 (+1.03%)
MU   73.48 (+0.48%)
CGC   0.73 (+4.01%)
GE   118.27 (-1.29%)
DIS   92.93 (+1.56%)
AMC   6.84 (+0.74%)
PFE   28.73 (-0.21%)
PYPL   58.22 (-2.20%)
XOM   98.62 (-0.49%)
S&P 500   4,584.47 (+0.77%)
DOW   36,092.99 (+0.11%)
QQQ   390.26 (+1.35%)
AAPL   194.74 (+1.26%)
MSFT   370.38 (+0.43%)
META   327.52 (+3.17%)
GOOGL   138.24 (+6.32%)
AMZN   147.00 (+1.72%)
TSLA   241.87 (+1.04%)
NVDA   462.66 (+1.68%)
NIO   7.45 (-3.87%)
BABA   72.19 (+0.98%)
AMD   125.26 (+7.22%)
T   17.08 (+0.83%)
F   10.80 (+1.03%)
MU   73.48 (+0.48%)
CGC   0.73 (+4.01%)
GE   118.27 (-1.29%)
DIS   92.93 (+1.56%)
AMC   6.84 (+0.74%)
PFE   28.73 (-0.21%)
PYPL   58.22 (-2.20%)
XOM   98.62 (-0.49%)
S&P 500   4,584.47 (+0.77%)
DOW   36,092.99 (+0.11%)
QQQ   390.26 (+1.35%)
AAPL   194.74 (+1.26%)
MSFT   370.38 (+0.43%)
META   327.52 (+3.17%)
GOOGL   138.24 (+6.32%)
AMZN   147.00 (+1.72%)
TSLA   241.87 (+1.04%)
NVDA   462.66 (+1.68%)
NIO   7.45 (-3.87%)
BABA   72.19 (+0.98%)
AMD   125.26 (+7.22%)
T   17.08 (+0.83%)
F   10.80 (+1.03%)
MU   73.48 (+0.48%)
CGC   0.73 (+4.01%)
GE   118.27 (-1.29%)
DIS   92.93 (+1.56%)
AMC   6.84 (+0.74%)
PFE   28.73 (-0.21%)
PYPL   58.22 (-2.20%)
XOM   98.62 (-0.49%)
S&P 500   4,584.47 (+0.77%)
DOW   36,092.99 (+0.11%)
QQQ   390.26 (+1.35%)
AAPL   194.74 (+1.26%)
MSFT   370.38 (+0.43%)
META   327.52 (+3.17%)
GOOGL   138.24 (+6.32%)
AMZN   147.00 (+1.72%)
TSLA   241.87 (+1.04%)
NVDA   462.66 (+1.68%)
NIO   7.45 (-3.87%)
BABA   72.19 (+0.98%)
AMD   125.26 (+7.22%)
T   17.08 (+0.83%)
F   10.80 (+1.03%)
MU   73.48 (+0.48%)
CGC   0.73 (+4.01%)
GE   118.27 (-1.29%)
DIS   92.93 (+1.56%)
AMC   6.84 (+0.74%)
PFE   28.73 (-0.21%)
PYPL   58.22 (-2.20%)
XOM   98.62 (-0.49%)

Eyenovia Stock Price, News & Analysis (NASDAQ:EYEN)

$1.41
+0.05 (+3.86%)
(As of 12:15 PM ET)
Compare
Today's Range
$1.35
$1.42
50-Day Range
$1.08
$1.72
52-Week Range
$1.05
$5.85
Volume
183,922 shs
Average Volume
331,617 shs
Market Capitalization
$62.32 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

Eyenovia MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
624.6% Upside
$10.00 Price Target
Short Interest
Bearish
4.44% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.50mentions of Eyenovia in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$19,062 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.68) to ($0.81) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.85 out of 5 stars

Medical Sector

697th out of 958 stocks

Pharmaceutical Preparations Industry

293rd out of 393 stocks


EYEN stock logo

About Eyenovia Stock (NASDAQ:EYEN)

Eyenovia, Inc., a pre-commercial ophthalmic company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. It focuses on developing clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi in rest of Asia. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is headquartered in New York, New York.

EYEN Stock Price History

EYEN Stock News Headlines

Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT?
A little-known metal called vanadium is vital to American national security and energy independence. But right now, China and Russia dominate our supply. The U.S. Govt. is so serious about vanadium, it funded and recently completed an "Earth MRI" survey to seek out new sources of this energy metal - in Wyoming.
Recent Reports Are A Wake-Up Call For Investors
As the demand for lithium, an essential element to the energy revolution, increases globally, researchers are projecting a supply deficit as early as 2025. This has sparked a worldwide "gold rush" to find and develop new sources of this critical metal. Savvy investors are paying attention as mining companies race to meet this critical deadline.
4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates
Eyenovia's Stock Is Soaring Today - Here's Why
Billionaire Marc Lasry’s Top 10 Stock Picks
H.C. Wainwright Keeps Their Buy Rating on Eyenovia (EYEN)
See More Headlines
Receive EYEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eyenovia and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/13/2023
Today
12/07/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
4/04/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EYEN
Fax
N/A
Employees
41
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.00
High Stock Price Target
$12.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+635.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-28,010,000.00
Pretax Margin
-2,541,699.75%

Debt

Sales & Book Value

Annual Sales
$14 million
Book Value
$0.48 per share

Miscellaneous

Free Float
40,680,000
Market Cap
$60.00 million
Optionable
Not Optionable
Beta
1.73
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report














EYEN Stock Analysis - Frequently Asked Questions

Should I buy or sell Eyenovia stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Eyenovia in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EYEN shares.
View EYEN analyst ratings
or view top-rated stocks.

What is Eyenovia's stock price target for 2024?

3 brokers have issued 1-year price objectives for Eyenovia's stock. Their EYEN share price targets range from $8.00 to $12.00. On average, they predict the company's stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 624.6% from the stock's current price.
View analysts price targets for EYEN
or view top-rated stocks among Wall Street analysts.

How have EYEN shares performed in 2023?

Eyenovia's stock was trading at $1.63 at the start of the year. Since then, EYEN shares have decreased by 15.3% and is now trading at $1.38.
View the best growth stocks for 2023 here
.

Are investors shorting Eyenovia?

Eyenovia saw a increase in short interest in November. As of November 15th, there was short interest totaling 1,960,000 shares, an increase of 12.0% from the October 31st total of 1,750,000 shares. Based on an average daily trading volume, of 266,200 shares, the short-interest ratio is presently 7.4 days.
View Eyenovia's Short Interest
.

When is Eyenovia's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our EYEN earnings forecast
.

How were Eyenovia's earnings last quarter?

Eyenovia, Inc. (NASDAQ:EYEN) issued its quarterly earnings results on Monday, November, 13th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.01.

What other stocks do shareholders of Eyenovia own?
When did Eyenovia IPO?

(EYEN) raised $30 million in an IPO on Thursday, January 25th 2018. The company issued 2,700,000 shares at $10.00-$12.00 per share. Ladenburg Thalmann and Roth Capital Partners​ acted as the underwriters for the IPO.

Who are Eyenovia's major shareholders?

Eyenovia's stock is owned by a variety of institutional and retail investors. Top institutional investors include Armistice Capital LLC (8.08%), Financial Management Network Inc. (0.21%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Bren Kern, Charles E Iv Mather, Ellen R Strahlman, John P Gandolfo, Kenneth B Lee Jr, Michael M Rowe, Michael M Rowe, Stuart M Grant and Tsontcho Ianchulev.
View institutional ownership trends
.

How do I buy shares of Eyenovia?

Shares of EYEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:EYEN) was last updated on 12/7/2023 by MarketBeat.com Staff

My Account -